HEMOTEK

Medtech · Private

V-Needle, a needle-integrated single-use safety device for hemodialysis that detects venous needle dislodgement and occludes blood flow to prevent catastrophic bleeding

Grants
$6.5M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$50K
1 award · Defense
#570 of 4531 in medtech
Patents
11
4 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · The V-Needle: A Failsafe Protection against Needle Dislodgement during Dialysis$654,935
Federal grantDepartment of Health and Human Services · Phase II · The V-Needle: A Failsafe Protection against Needle Dislodgement during Dialysis$838,823
Federal grantDepartment of Health and Human Services · Phase II · Phase IIB: Exploratory Clinical trials for The V Needle$2,982,000
Federal grantDepartment of Health and Human Services · Phase II · Phase IIB: Exploratory Clinical trials for The V Needle$994,000
Federal contractDepartment of Defense · Hemotek OX66 Powdered Oxygen$49,920
Federal grantDepartment of Health and Human Services · Phase II · Phase IIB: Exploratory Clinical trials for The V Needle$994,000
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
567MILLAR INC.$51K—
568OTO-BIOMECHANICS LLC$50K—
569SAFEBVM CORP.$50K—
570HEMOTEK$50K—
571MR3 Health, Inc.$50K$1.1M
572SHIFT LABS, INC.$50K$1.5M
573BB MEDICAL SURGICAL, INC.$50K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 11

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.